Jordan Axelrad, MD, MPH

home / authors / jordan-axelrad-md-mph

Articles

The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

Jamie T. Brogan, MSN, APRN, FNP-BC;Kostas N. Botsoglou, MD;Jordan Axelrad, MD, MPH;Sophia Humphreys, PharmD, MHA;Peter Lio, MD

March 29th 2024

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Concurrent Management of Inflammatory Bowel Disease and Psoriatic Arthritis

David P. Hudesman, MD;Jordan Axelrad, MD, MPH;Jose Scher, MD

May 9th 2023

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

Concurrent Management of Inflammatory Bowel Disease and Psoriatic Arthritis

David P. Hudesman, MD;Jordan Axelrad, MD, MPH;Jose Scher, MD

May 2nd 2023

Exploring the Evolving Treatment Landscape for Inflammatory Bowel Disease

David P. Hudesman, MD;Jordan Axelrad, MD, MPH;Douglas Wolf, MD

May 2nd 2023

Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.

Exploring the Evolving Treatment Landscape for Inflammatory Bowel Disease

David P. Hudesman, MD;Jordan Axelrad, MD, MPH;Douglas Wolf, MD

April 26th 2023

Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.

Restoring Balance with Advanced Fecal Microbiota Transplantation in C difficile Infections

David P. Hudesman, MD;Jordan Axelrad, MD, MPH;Paul Feuerstadt, MD

April 18th 2023

Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.

<1 2